Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin
(GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response
and safety between the two drug combinations for the treatment of advanced non-small cell
lung cancer (NSCLC).